{"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}],"groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG001","title":"Cohort B: CP-CML With T315I Mutation"},{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG002","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG003","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG004","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG005","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"},{"description":"Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not resistant or intolerant to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"BG006","title":"Unassigned to Cohorts A-F"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"94","value":"61.0"},{"groupId":"BG001","lowerLimit":"18","upperLimit":"87","value":"52.0"},{"groupId":"BG002","lowerLimit":"23","upperLimit":"82","value":"60.0"},{"groupId":"BG003","lowerLimit":"24","upperLimit":"78","value":"54.0"},{"groupId":"BG004","lowerLimit":"18","upperLimit":"74","value":"54.0"},{"groupId":"BG005","lowerLimit":"18","upperLimit":"80","value":"56.0"},{"groupId":"BG006","lowerLimit":"51","upperLimit":"71","value":"63.0"},{"groupId":"BG007","lowerLimit":"18","upperLimit":"94","value":"59.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"211"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"238"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"42"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"46"},{"groupId":"BG005","value":"34"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"407"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}],"title":"American Indian/Alaska native"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"59"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"25"}],"title":"Black/African American"},{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"39"},{"groupId":"BG005","value":"38"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"352"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"8"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"3"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"267"}],"title":"ECOG=0"},{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"147"}],"title":"ECOG=1"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"34"}],"title":"ECOG=2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"448"}],"units":"Participants"}]}],"description":"ECOG-PS measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\\>50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \\>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant from the cohort F had missing ECOG data.","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.45","upperLimit":"27.43","value":"7.85"},{"groupId":"BG001","lowerLimit":"1.16","upperLimit":"19.49","value":"4.78"},{"groupId":"BG002","lowerLimit":"0.33","upperLimit":"28.47","value":"7.13"},{"groupId":"BG003","lowerLimit":"1.17","upperLimit":"15.90","value":"6.61"},{"groupId":"BG004","lowerLimit":"0.62","upperLimit":"27.21","value":"3.96"},{"groupId":"BG005","lowerLimit":"0.46","upperLimit":"14.14","value":"1.63"},{"groupId":"BG006","lowerLimit":"1.74","upperLimit":"18.60","value":"4.80"},{"groupId":"BG007","lowerLimit":"0.33","upperLimit":"28.47","value":"6.09"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"48"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"449"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time From Diagnosis to First Dose","unitOfMeasure":"years"}],"populationDescription":"The safety population included all participants who received at least 1 dose of ponatinib."}